Our objectives were to investigate the seroprevalence of IgG and IgM SARS-CoV-2 antibodies of recovered COVID-19 patients in long-term follow-up studies (follow-up time ≥ 6 months). The gene discussed is CD40LG; the disease is COVID-19.